

MTN 001 Study-Specific Procedures Manual
TABLE OF CONTENTS

- 1 Introduction
 - 1.1 Sources of Procedural Information
 - 1.2 Investigator Responsibilities
 - 1.3 Study Activation Process
 - 1.4 IRB/EC Submissions

- 2 Protocol

- 3 Documentation Requirements
 - 3.1 Essential Documents
 - 3.2 Participant Case History Documentation
 - 3.2.1. Case History Contents
 - 3.2.2. Concept of Source Data and Source Documentation
 - 3.2.3. Document Organization
 - 3.3 Study Product Accountability, Chain of Custody, and Dispensing Documentation
 - 3.4 Record Retention Requirements

- 4 Participant Accrual
 - 4.1 Study Accrual Plan and Site-Specific Accrual Targets
 - 4.2 Screening and Enrollment
 - 4.2.1. Definition of Screening
 - 4.2.2. Definition of Enrollment
 - 4.2.3. Screening and Enrollment Timeframe
 - 4.2.4. Screening and Enrollment Logs
 - 4.2.5. Assignment of Participant ID Numbers
 - 4.2.6. Screening HIV Testing
 - 4.2.7. Random Assignment
 - 4.2.7.1.Replacing Participants
 - 4.2.8. Prescription Overview
 - 4.2.8.1.Participant-Specific Procedures

- 5 Informed Consent
 - 5.1 Overview of Informed Consent Requirements and Procedures
 - 5.2 Informed Consent for Screening
 - 5.3 Informed Consent for Enrollment
 - 5.3.1. Informed Consent Support Materials
 - 5.3.2. Comprehension Assessment
 - 5.4 Informed Consent for Specimen Storage and Possible Future Research Testing
 - 5.5 Documenting the Informed Consent Process

MTN 001 Study-Specific Procedures Manual
TABLE OF CONTENTS

- 6 Participant Follow-up
 - 6.1 Study Follow-up Plan and Retention Targets
 - 6.2 Types of Follow-up Visits
 - 6.3 Follow-up Visit Scheduling
 - 6.3.1. Target Visit Dates
 - 6.3.2. Allowable Visit Windows
 - 6.3.3. Visits Conducted Over Multiple Days: “Split Visits”
 - 6.3.4. Missed Visits
 - 6.3.5. Follow-up Visit Scheduling Scenarios
 - 6.4 Follow-up Visit Procedures
 - 6.5 Follow-up Visit Locations
 - 6.6 Product Re-Supply During Follow-up
 - 6.6.1. MTN 001 Study Product Hold/Resume/PK Supply Slip
 - 6.7 HIV Testing During Follow-up
 - 6.8 Modified Follow-up Procedures for Participants Who Become Pregnant
 - 6.9 Modified Follow-up Procedures for Participants Who Become Infected with HIV
 - 6.10 Participant Transfers
 - 6.11 Resumption of Study Participation After Voluntary withdrawal
 - 6.12 Study Exit Considerations
 - 6.12.1. Certificate of Completion
 - 6.12.2. Participant Locator Information
 - 6.12.3. Final Study Contacts
 - 6.12.4. HIV Counseling and Testing
 - 6.12.5. Plasma Archive
 - 6.12.6. Product Hold/Discontinuation
 - 6.12.7. AE Management and Documentation
 - 6.12.8. Referral to Non-Study Service Providers
 - 6.12.9. Post-Study Contacts
- 7 Visit Checklists
 - 7.1 Use of Checklists
 - 7.2 Sequence of Procedures
- 8 Participant Retention
 - 8.1 Retention Definitions
 - 8.2 Retention Requirements
 - 8.3 Retention SOPs
 - 8.4 Obtaining and Updating Locator Information
 - 8.5 Retention Tips
- 9 Study Product Considerations
 - 9.1 Gel Use Instructions
 - 9.2 Pill Use Instructions
 - 9.3 Observed dose of study product at End of Study Period Visits
 - 9.4 Distributing Study Product During Visits
 - 9.4.1. Dispensing from the Pharmacy Directly to Participants

MTN 001 Study-Specific Procedures Manual
TABLE OF CONTENTS

- 9.4.2. Dispensing from the Pharmacy to Clinic Staff
- 9.4.3. Dispensing from the Pharmacy to Runners for Further Transfer to Clinic Staff
- 9.5 Return of Study Product Supplies
 - 9.5.1. Unused Product Supplies
 - 9.5.2. Used Gel Supplies
- 10 Clinical Considerations
 - 10.1 Baseline Medical/Menstrual/Genitourinary History and Ascertainment of Concomitant Medications
 - 10.1.1. Focused Baseline Medical/Menstrual/Genitourinary/Genitourinary History
 - 10.1.2. Initial Ascertainment of Concomitant Medications
 - 10.1.3. Pre-existing Conditions
 - 10.2 Interval Medical/Menstrual/Genitourinary History and Updating of Concomitant Medications
 - 10.2.1. Interval Medical/Menstrual/Genitourinary History
 - 10.2.2. Updating of Concomitant Medications Information
 - 10.3 Physical Exams
 - 10.4 Pelvic Exams
 - 10.4.1. Overview
 - 10.4.2. Detailed Procedural Instructions
 - 10.4.3. Documentation of Findings
 - 10.5 Genital Bleeding Assessment
 - 10.5.1. Genital Bleeding Assessment for Pregnant Participants
 - 10.5.2. Participant Reports of Genital Bleeding
 - 10.5.3. Clinician Assessment of Genital Bleeding
 - 10.5.4. Documentation of Genital Bleeding
 - 10.6 STI/RTI Management
 - 10.6.1. STI/RTI Treatment
 - 10.6.2. Screening and Enrollment Considerations
 - 10.6.3. Adverse Event Reporting Considerations
 - 10.7 Urinary Tract Infections
 - 10.8 Management of Laboratory Abnormalities
 - 10.8.1. ALT/AST Elevation
 - 10.8.2. Hypophosphatemia
 - 10.8.3. Creatinine Clearance
 - 10.9 Pharmacokinetic Procedures
 - 10.9.1. Mid-Study Period
 - 10.9.2. End of Study Period
 - 10.9.2.1 Non-Intensive PK
 - 10.9.2.2 Intensive PK
 - 10.10 Product Use Management
 - 10.10.1. Circumstances In Which Product Use Must Be Either Temporarily Held or Permanently Discontinued
 - 10.10.2. Circumstances In Which Product Use May Be Either Temporarily Held or Permanently Discontinued
 - 10.10.3. Documentation of Product Use Management

MTN 001 Study-Specific Procedures Manual
TABLE OF CONTENTS

- 10.10.4. Participant Follow-Up During Periods of Product Use Discontinuation
- 10.10.5. Collection of Product Supplies During Periods of Product Use Discontinuation
- 10.11 Pregnancy Management

- 11 Adverse Event Reporting and Safety Monitoring
 - 11.1 Definitions and General Reporting Guidance
 - 11.1.1. Adverse Event
 - 11.1.2. Serious Adverse Event
 - 11.1.3. Expedited Adverse Event
 - 11.1.3.1. EAEs Reporting Requirements
 - 11.2 Adverse Event Terminology
 - 11.3 Adverse Event Severity
 - 11.4 Adverse Event Relationship to Study Product
 - 11.5 Adverse Event Outcomes and Follow-up Information
 - 11.6 Reporting Recurrent Adverse Events
 - 11.7 Social Harms
 - 11.8 MTN 001 Safety Monitoring, Review, and Oversight
 - 11.9 Safety Distributions from DAIDS

- 12 Laboratory Considerations
 - 12.1 Overview and General Guidance
 - 12.2 Specimen Labeling
 - 12.3 Procedures for Specimens that can not be evaluated
 - 12.4 Use of LDMS
 - 12.5 Urine Testing for Pregnancy, Dipstick, Chlamydia, and Gonorrhea
 - 12.5.1. Specimen Collection
 - 12.5.2. Dipstick Urinalysis
 - 12.5.3. Pregnancy Testing
 - 12.5.4. Chlamydia and Gonorrhea Testing
 - 12.6 Blood Specimens for HIV testing, Syphilis, Hematology, Chemistries, PBMC for Intracellular Tenofovir, Blood Tenofovir, Hepatitis B Surface Antigen, Flow Cytometry and Plasma Archive
 - 12.6.1. Specimen Collection and Initial Processing
 - 12.6.2. HIV Testing
 - 12.6.3. Syphilis Testing
 - 12.6.4. Hematology Testing
 - 12.6.5. Serum Chemistries
 - 12.6.6. Plasma archive
 - 12.6.7. Serum Tenofovir
 - 12.6.8. Hepatitis B Surface Antigen
 - 12.6.9. Peripheral Blood Mononuclear Cells for Intracellular Tenofovir
 - 12.6.10. Flow Cytometry for CD38 and CD95
 - 12.7 Testing of Vaginal and Cervical Specimens
 - 12.7.1. Vaginal pH
 - 12.7.2. Vaginal Fluid Wet Mount Testing

MTN 001 Study-Specific Procedures Manual
TABLE OF CONTENTS

- 12.7.3. Cytobrush Collection and Storage
- 12.7.4. Cervicovaginal Lavage (CVL)
- 12.7.5. Vaginal Biopsy
- 12.7.6. Herpes Culture
- 12.7.7. Papanicolaou (Pap) Test

- 13 Data Collection
 - 13.1 DataFax Overview
 - 13.2 DataFax Form Completion
 - 13.2.1. Guidelines
 - 13.2.2. How to Mark Response Boxes
 - 13.2.3. How to Record Numbers
 - 13.2.4. How to Record Dates
 - 13.2.5. How to Record Time
 - 13.2.6. Data Corrections and Additions
 - 13.2.7. How to Handle Missing and Unknown Data
 - 13.3 MTN 001 Study-Specific Data Collection Information
 - 13.3.1. Participant ID Numbers (PTIDs)
 - 13.3.2. Study Visit Timing
 - 13.3.3. Visit Codes and Page Numbers
 - 13.3.4. Staff Initials/Date
 - 13.3.5. Case Report Form Completion Schedule
 - 13.3.6. Site Review of DataFax Forms
 - 13.3.7. Faxing DataFax Forms
 - 13.3.8. Non-DataFax Forms
 - 13.4 Form Supply and Storage
 - 13.4.1. Form and Specimen Label Supply
 - 13.4.2. Form Storage
 - 13.5 How to Complete Interviewer-administered Forms
 - 13.6 Form Completion
 - 13.7 Case Report Forms

- 14 Data Communiqués

- 15 Study Reporting Plan
 - 15.1 Purpose of Reporting Plan
 - 15.2 Study Reports
 - 15.2.1. Data Quality Control (QC) Report
 - 15.2.2. Clinical Data Quality Control (CQC) Queries
 - 15.2.3. Study Monitoring Committee Report
 - 15.2.4. Site Specimen Repository Report
 - 15.2.5. Summary Specimen Repository Report
 - 15.2.6. Enrollment and Retention Report
 - 15.2.7. Visit Adherence and Procedure Completion Report
 - 15.2.8. Site Data Management Quality Report
 - 15.2.9. Safety Report

MTN 001 Study-Specific Procedures Manual
TABLE OF CONTENTS

- 15.2.10. Network Lab Assay Results Report

- 16 Week 21 In-Depth Interviews
 - 16.1 Introduction
 - 16.2 Target Number of Participants
 - 16.3 Participants Reporting Differential Adherence
 - 16.3.1. Identification of Participants Reporting Differential Adherence
 - 16.4 Data Collection
 - 16.4.1. General Preparation Prior to Interview
 - 16.4.2. Reiterating Informed Consent
 - 16.4.3. Style of Interviewing
 - 16.4.4. Digital recording and managing voice files
 - 16.4.5. Recording Preparation Prior to Interview
 - 16.4.6. Recording the interview
 - 16.4.7. Procedures Following the Interview
 - 16.4.8. Backup, storage and transmission of voice files
 - 16.5 Data Collation and Management
 - 16.5.1. Transcriptions
 - 16.5.2. Translations
 - 16.5.3. Data Management and Storage
 - 16.5.4. Electronic files
 - 16.5.5. Data tracking and storage
 - 16.6 Data tracking and storage
 - 16.6.1. Site Investigator responsibilities
 - 16.6.2. Data monitoring